Eli Lilly and Company News

126,27 $ -5,44% -7,26 $
In : 115,16 € | 15:40:03 Uhr NYSE | Mehr Kurse »
WKN: 858560
ISIN: US5324571083
US-Symbol: LLY
Typ: Aktie
Werbung
präsentiert ausgewählte Knock Out Produkte auf den Basiswert:

Eli Lilly and Company

Kurs Typ Hebel Bid / Ask WKN Typ Hebel Bid / Ask WKN
126,27 $
Call
5,1 2,05 € / 2,06 €
GA9JN5
mehr
Put
5,0 2,58 € / 2,59 €
GB6QLR
mehr
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie hier: GA9JN5 , GB6QLR . Beachten Sie auch die weiteren Hinweise * zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Jetzt für 4€ handeln

Eli Lilly and Company News

  
Mi FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-​Line Treatment for Metastatic EGFR-​Mutated Non-Small Cell Lung Cancer PR Newswire
Di Aktie von Eli Lilly läuft heute schlechter ARIVA.DE
21.02.20 Lilly to Participate in Cowen Health Care Conference PR Newswire
21.02.20 Lilly To Participate in SVB Leerink Global Healthcare Conference PR Newswire
21.02.20 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease PR Newswire
20.02.20 Lilly Completes Acquisition of Dermira PR Newswire
10.02.20 Thinking about buying stock in L Brands, Eli Lilly, Netflix, Tesla, or Xylem? PR Newswire
10.02.20 Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study PR Newswire
07.02.20 Lilly to Participate in Guggenheim Healthcare Talks Idea Forum PR Newswire
06.02.20 Thinking about trading options or stock in Apple, Eli Lilly, Microchip Technology, Tesla, or UnitedHealth Group? PR Newswire
31.01.20 Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription PR Newswire
31.01.20 CHMP Recommends Approval of Lilly's New Fast-​Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes PR Newswire
30.01.20 Thinking about buying stock in Applied Materials, General Electric, Eli Lilly, Qorvo, or Tesla? PR Newswire
30.01.20 Pharmariese Elli Lilly profitiert von neuen Medikamenten - mehr Umsatz erwartet dpa-AFX
30.01.20 Lilly Reports Strong Fourth-​Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition PR Newswire
30.01.20 Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis PR Newswire
29.01.20 Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application PR Newswire
28.01.20 Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-​income communities PR Newswire
27.01.20 US FDA approves only triple-​combination tablet with Jardiance® for adults with type 2 diabetes PR Newswire
27.01.20 Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine PR Newswire
24.01.20 Anat Hakim to join Lilly as General Counsel PR Newswire
21.01.20 Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant PR Newswire
16.01.20 Lilly Confirms Date and Conference Call for Fourth-​Quarter 2019 Financial Results Announcement PR Newswire
15.01.20 Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease PR Newswire
14.01.20 Lilly expands insulin affordability options with lower-​priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® PR Newswire
13.01.20 Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-​Line Therapy in Nonsquamous NSCLC PR Newswire
12.01.20 Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-​Line Therapy in Nonsquamous NSCLC PR Newswire
10.01.20 ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc. PR Newswire
10.01.20 Lilly Announces Agreement to Acquire Dermira PR Newswire
09.01.20 Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-​Controlled Robotic Cloud Lab PR Newswire
02.01.20 Lilly to Participate in J.P. Morgan Healthcare Conference PR Newswire
31.12.19 Eli Lilly and Company Aktie: Das sollte man sich durch den Kopf gehen lassen … Finanztrends
30.12.19 U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit PR Newswire
30.12.19 Lilly Opens Phase 3 Clinical Trial in RET-​Mutant Medullary Thyroid Cancer PR Newswire
19.12.19 Thinking about trading options or stock in Apple, Axsome Therapeutics, Deere & Co, Johnson & Johnson, or Eli Lilly? PR Newswire
19.12.19 Lilly Launches Campaign to Increase Awareness of Insulin Cost-​Saving Options PR Newswire
19.12.19 Eli Lilly rechnet mit starkem Geschäftsjahr 2020: Ernsthafte Bedrohung für Novo Nordisk? The Motley Fool
18.12.19 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-​World Evidence Study of Emgality® (galcanezumab-​gnlm) PR Newswire
17.12.19 Lilly Announces 2020 Financial Guidance, Updates 2019 Guidance PR Newswire
16.12.19 Lilly Announces 15 Percent Dividend Increase PR Newswire
16.12.19 Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System PR Newswire
13.12.19 Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure PR Newswire
13.12.19 CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-​Mutated Non-Small Cell Lung Cancer PR Newswire
11.12.19 Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-​Positive Non-Small Cell Lung Cancer PR Newswire
08.12.19 Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting PR Newswire
05.12.19 Lilly Announces New Leadership and Strategy in Oncology Research and Development PR Newswire
02.12.19 Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference PR Newswire
02.12.19 Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco PR Newswire
02.12.19 Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD) PR Newswire

Newssuche